Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant–dependent lung carcinomas
J. Clin. Invest. Danan Li, et al. 117:346 doi:10.1172/JCI30446 [Go to this article.]

Figure 3
Western blot analysis of whole lung lysates from mAb806-treated Tet-op-EGFRvIII/CCSP-rtTA, Ink4A/Arf^–/– mice. Whole lung lysates from mice at different time points of mAb806 treatment were analyzed. Inhibition of EGFR phosphorylation was observed after 1 week of treatment, while total EGFR levels decreased after 5 weeks of treatment. Erk1/2 phosphorylation was inhibited throughout the mAb806 administration; Akt phosphorylation decreased at 1 week of treatment and slightly increased after 5 weeks of treatment when compared with the 1-week time point. β-Actin served as a loading control.